Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.

Raquel AlvesStephanie E B McArdleJayakumar VadakekolathuAna Cristina GonçalvesPaulo Freitas-TavaresAmélia PereiraAntonio M AlmeidaAna Bela Sarmento-RibeiroSergio Rutella

Published in: Journal of translational medicine (2020)

Our results suggest that TKIs in combination with IFN-α may promote an enhanced immune suppressive state.

Keyphrases

chronic myeloid leukemia
flow cytometry
dendritic cells
single cell
immune response
cancer therapy